🇺🇸 FDA
Pipeline program

zongertinib

1479-0008

Phase 3 small_molecule active

Quick answer

zongertinib for Lung Cancer, Non-squamous, Non-small Cell is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim
Indication
Lung Cancer, Non-squamous, Non-small Cell
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials